Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

BICO, Audiocast, Q2'26

By Inderes8/19/2026, 8:00 AM
BICO Group

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Erik Gatenholm
00:01 - 02:10

Thank you, everyone, for joining us today. It's a great pleasure to be here. My name is Erik Gatenholm, and I am here today in my capacity as chairman of the board. We will spend the first few minutes of this earnings call commenting on the press release published yesterday evening regarding the leadership transition. We will then proceed with the BICO Group Q2 Earnings Call. Today, I have the pleasure of having Maria Forss, CEO, Ewa Linsäter, CFO, and Anders Fogelberg, current CEO and incoming CEO, on the call. The purpose of my remarks is to provide the Board of Directors' perspective on yesterday's announced leadership transition. After constructive discussions with Maria Forss, the Board of Directors concluded that this is the right time for a leadership change as BICO Group AB enters its next phase of development with an amplified focus on commercialization, customer engagement, and profitable growth. The Board is pleased to appoint Anders Fogelberg as President and CEO, effective September 1st. As Chief Commercial Officer and a member of the executive management team since 2024, he has already played an important role in driving global commercial execution and advancing key market positions. He has already played an important role in driving global commercial execution and advancing key market positions. I would also like to sincerely thank Maria Forss for her contributions and dedication to BICO Group AB. Maria, you have, together with the team, played an important role in strengthening the financial position, strengthening the balance sheet from a net debt of 877 million Swedish crowns to a net cash position of 207 million Swedish crowns and improved net working capital from 27% to 10%, improving operational discipline and integrating acquired companies into a more streamlined organization. Thanks to Maria, the company now stands on firmer ground and is better positioned for the next phase of development. On behalf of the Board of Directors, I would like to wish you all the success in the future and at the same time, give Anders Fogelberg a very warm welcome to this new role. I now hand over the floor to you. Maria Forss.

Maria Forss
02:10 - 02:37

Thank you, Erik. It's been a privilege to lead BICO Group AB during an important period of transformation, and I have worked closely with Anders during the past years, and I'm confident in his ability to lead the company moving forward. Anders knows the organization. He knows our customers, our strategy, and opportunities well, and I look forward to supporting a seamless handover over the coming months. And I wish him and the entire team every success.

Anders Fogelberg
02:38 - 03:49

Thank you Eric. Thank you, Maria. I am honored to be appointed President and CEO of BICO Group AB. Having served as Chief Commercial Officer and a member of the Executive Management team, I've had the opportunity to work closely with our colleagues, customers, and partners around the world. I have a strong passion for this industry and the important work that our people and our customers perform every day. I have been prioritizing deep customer engagement, operational excellence, and profitable growth since joining the company, and I will continue to do so. Also, in my new role, BICO has an attractive position at the intersection of automation, intelligence, and life science workflows, serving leading pharma and biotech customers globally. The opportunity ahead is substantial. My immediate priority is execution supporting our customers, driving commercial performance, improving operational efficiency, and delivering sustainable, profitable growth. And I really look forward to engaging with all of you over the coming months.

Erik Gatenholm
03:52 - 04:00

Thank you, Maria and Anders. I now hand over the word to Maria and Ewa to present the BICO Q2 earnings report.

Maria Forss
04:01 - 08:38

Thank you, Eric, and thank you, Anders. I will continue today's session by summarizing the second quarter of 2026 and also describe how BICO Group AB serves the world's leading pharma and biotech companies with solutions that transform how labs operate, innovate, and solve our customer challenges. Following that, Ewa will then present the group's financial performance. I will also comment on our R&D pipeline and our ongoing product development efforts. Additionally, I will highlight some recent product launches. The session will then conclude. And before we open up our Q&A about the financial results. In the quarter, we saw continued good sales momentum navigating a dynamic market still affected by geopolitical uncertainty. But we are gaining confidence in a gradual market recovery. Although the academic end markets remain soft due to reduced funding. Sales amounted to 336 million SEK, an organic growth in local currencies of 7%, mainly derived from continued strong benchtop instrument and consumable sales, while still experiencing challenges in the project-based business due to continued currency headwinds. Our total growth was 4% in the second quarter. We also see an improved profitability in the quarter as commercial and operational excellence activities are paying off, decreasing our overall costs, resulting in an adjusted EBITDA of 20 million SEK or an adjusted EBITDA margin of 6%. Cash flow from operating activities totaled -53 million SEK, which is mainly stemming from changes in net working capital after the period ended. One of our business units successfully signed long-term supply and license agreements as a prolongation of its ongoing business with one of its current customers, and the agreements have a combined contracted value of approximately €50 million over a ten-year term. All numbers presented are in million SEK unless otherwise stated. Before Ewa provides more details on our financial performance, I will present how BICO serves the world's leading pharma and biotech companies with solutions that transform how labs operate and innovate, which is what our mission is about. BICO supports customers to advance science so that therapies can reach patients faster. Our solutions, with predominantly benchtop instruments, enable smarter, faster, and more efficient labs in which we see an underlying strong demand. Pharma and Biotech companies all face the same fundamental challenge: long and costly development cycles for new therapies, and the development of a new therapy often takes more than ten years and costs between 2 and 4 billion USD, with the probability of approval after phase one at just 10%. And to overcome this, our pharma and biotech customers are investing heavily in automation and AI to increase efficiency, speed and quality, to bring innovations to market faster and at lower cost. AI accelerates discovery, and then the wet labs become the new bottleneck. Generative models and predictive biology dramatically speed up hypothesis generation. Wet lab automation and validation. Wet lab automation and validation remains the hard constraint. In fact, more AI-driven candidates mean more experiments, not fewer. Intensifying pressure on lab throughput, system uptime, and data reproducibility. This means that wet labs have become more critical than obsolete. AI breakthroughs have made wet labs even more central to R&D, and the lab is now a biological compute cluster, validating AI predictions. So high-throughput automation and trusted data become mission-critical. Customers using BICO lab automation solutions consistently report measurable gains in productivity and reliability, including reduced hands-on time, faster turnaround time, and higher instrument utilization. So to summarize, BICO leads the way in solving the challenges in life science with speed, accuracy, and efficiency. All in all, our customers can run their processes faster, improve the quality of the data, and ultimately make better decisions. And I will now hand over to Ewa Linsäter to present the results for the second quarter.

Ewa Linsäter
08:40 - 15:07

Thank you Maria. I will now provide further details regarding the figures presented by Maria. Navigating these dynamic market conditions. Sales in Q2 amounted to 336 million, representing organic growth of 7% compared to a weak comparison quarter. Due to the continued currency headwinds, our total growth was 4%. As Maria mentioned, the commercial and operational excellence activities are paying off, decreasing our overall costs, leading to an improvement in Adjusted EBITDA of 21 percentage points, resulting in an Adjusted EBITDA margin of 6%. While the market will experience geopolitical uncertainty, we are gaining confidence in gradual market recovery. Although the US academic end markets remain soft due to reduced funding, sales amounted to 336 million. We achieved organic growth in local currencies of 7%, with continued good momentum in our benchtop instruments business while still experiencing challenges in the project-based business. Also, consumables had a positive development during the quarter and grew by 10%. Last year's sales were negatively impacted by a re-estimation of remaining project hours of approximately 40 million. Due to project delays in our integrated lab automation project business. Excluding this adjustment, organic growth was -4%. We see growth year on year in Europe and Asia, while North America is declining. As expected, the decline in North America is due to continued soft academic funding as well as the timing of customer projects within our European-based diagnostic business. While the underlying demand remains within the diagnostic business, the industry continues to experience longer lead times for larger automation investments, extending the uncertainty around sales cycles. The emerging market for integrated lab automation solutions is in a transformation phase, where the pace of development and the competitive landscape have changed substantially. As described in Q1, we see execution challenges in part of our US-based integrated lab automation solution business in combination with lower demand as the legacy projects are nearing completion. The US business has been rightsized to align with current staffing requirements. We are now reassessing our position in the market to regain trust and grow the business for integrated lab automation solutions in a sustainable way. We saw a substantially improved gross profit margin this quarter, from 44% in Q2 last year to 59% this year. Part of the improvement is due to the negative adjustment from updated cost estimation in ongoing projects within the Integrated Lab Automation project business last year, but the improvement in gross margin this year is due to continued favorable product mix and higher share of direct sales. EBITDA amounted to 60 million SEK, with adjusted EBITDA being 20 million SEK. The difference relates to a restructuring provision of 4.5 million in relation to our US-based project business. Adjusted EBITDA margin improved by 2.1 percentage points, resulting in an adjusted EBITDA margin of 6%. Excluding last year's 40 million SEK adjustment, EBITDA margin improved from -2.6% last year to 6.6% this year. The improvement was mainly driven by our commercial and operational excellence initiatives, supported by a favorable product mix. Operating expenses decreased by 7% year-over-year. During the quarter, we launched a group-wide program to identify opportunities to improve how we work and further streamline core processes across the group. The program focused on areas with clear potential for standardization, automation, and efficiency gains across the full value chain, primarily related to our ERP system. The restructuring project launched in Q1 aimed at improving cost efficiency and R&D pipeline execution by consolidating the activities from the site in Lyon to Berlin. The project progresses successfully, and the completion of the project is expected this fall. The anticipated annualized savings from the project of 30 million SEK communicated in Q1 remain fully achievable. The effects will start to materialize in the second half of the year. Cash flow from operating activities amounted to -53 million, impacted by a negative net working capital change of 54 million, mainly derived from lower accounts payable and increased accounts receivable, as well as inventory of raw materials. Cash reserves by the end of the period were 628 million, of which 57 million were restricted. As mentioned on the previous slide, the effect of changes in working capital amounted to -54 million compared to the previous quarter. Operating receivables increased by 15 million SEK, mainly in relation to accounts receivable. Inventories increased by 6 million, mainly in relation to raw materials. Operating liabilities decreased by 33 million, mainly in relation to accounts payable as a percentage of the last 12 months. Sales net working capital in the quarter corresponded to 10%. Over time, we expect working capital in relation to sales to be in line with industry standards of closer to 20% of sales. I will now hand over to Maria to present the R&D portfolio and some recent product launches.

Maria Forss
15:10 - 17:55

Thank you, Ewa. One focus area for growth is continuous product innovation. And we have a solid R&D pipeline and roadmap in place, which is based on the portfolio strategy being part of BICO AB 2.0. Multiple product launches are planned for this year, and these include software, instruments, and consumables. The fast development of AI is an opportunity for BICO Group AB as AI accelerates discovery and shifts the bottleneck to the wet lab, as I described earlier in this call. And this is where our automation solutions are at the core. We had two key launches during the quarter: G.PURE GEN 2, which automates DNA purification, and yet another AI solution, this time for cell culture workflows. Our Confluency AI turns one of cell culture's most subjective steps into a quantitative, reproducible metric, which we deliver as a licensed software feature to our Rebel and Revolve systems. Already in the field, Confluency AI is built directly into our microscopes through our software to detect and calculate the number of cells more reliably. This removes subjectivity and improves decision-making timing as well as reproducibility. At launch this quarter is the G.PURE GEN 2, which automates DNA purification, delivering rapid, reproducible, plastic-tip-free sample cleanup for seamless NGS library prep workflows. And this saves the use of 300,000 pipette tips per year for a mid-sized laboratory. It is also ten times faster, which significantly increases the throughput. And saving 18 minutes per plate means roughly four working weeks of technician time per instrument per year. And these are just two examples of technology and solutions delivering customer value. These are the results of our efforts within R&D. This will be my last quarterly report for the group, and I'm proud of what we have accomplished together during my tenure. We have focused on commercializing, consolidating, and professionalizing the group to position the company for long-term success. I now hand over the leadership to Anders Fogelberg, in whom I have great confidence, and I wish him every success in the next chapter and look forward to following BICO's continued development as the group enters an exciting new phase. Thank you to our employees, our customers, partners, shareholders, and the board for your support and commitment throughout this journey. This was the final slide before the Q&A. I will hand over to the earnings call host for further instructions.

Operator
17:58 - 18:15

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Ludvig Lundgren from Arctic. Please go ahead.

Ludvig Lundgren
18:18 - 19:00

Yes. Hi everyone, and thank you for taking my questions. I wanted to start off a bit on the license and supply agreement, which I argue deserves a bit more spotlight given the significant effect it should have on the P&L here in Q3. So starting off on the last part of it, about €11 million, which will be recorded as revenue in Q3. I understand that correctly. So, I assume this relates to another company licensing your micro-dispensing technology. So maybe if you can just give some flavor on what type of IP they're licensing, what type of product that this goes into, and the end market for that, if you can just give some more flavor, that would be nice.

Ewa Linsäter
19:02 - 19:11

So, this is with our diagnostic business. So, it is a technology license that we have with the customer.

Ludvig Lundgren
19:16 - 19:24

Okay. Thanks. And just on the margin for this license agreement, I suppose this is a bit higher than what you have for the instruments. Typically.

Ewa Linsäter
19:27 - 19:32

We do not comment on margins for specific products or licenses. I apologize for that.

Ludvig Lundgren
19:33 - 20:13

Okay. Fair enough. Then just to follow up, I understand this is a license agreement that you have now and have had in the past. But I guess this spans over many years. So, have we seen this type of negotiation before in big numbers? Or was it negotiated before the company was even acquired by BICO, and what is the cash flow profile of this agreement? So I assume you won't get the full cash flow here in Q3 for the revenue. But, just how it expands over the next few years would be nice. Yeah. Some more.

Maria Forss
20:13 - 21:13

Thank you, Ludwig, for the question; I will start by answering in terms of what this has been before. And then I'll hand over to Ewa Linsäter to answer about the financial implications accounting-wise. So this type of agreement. There are two agreements, one license agreement and one supply agreement, which are a prolongation of earlier business that we have done with this customer. And given the tenure of these types of contracts, this was the original contract, which was signed with the customer prior to acquiring Cellenion. So, we have not communicated this to the market before. These contracts were not communicated to the market before, but it has been a long negotiation with the customer for this prolongation. Given the nature of the supply agreement as well as the license agreement over a tenure of ten years, that has some accounting and cash flow implications. And please, if you can give some more flavor on that, that would be helpful.

Ewa Linsäter
21:14 - 21:45

So, as you can see in the report for the license, we will recognize €10.6 million at the point of time in Q3. So that is the revenue recognition of the license part that is non-cancellable, and according to IFRS, we need to recognize it at a point in time. That means that it will deviate from the cash flow. So the cash flow will be invoiced on a yearly basis going forward, but the revenue will be recognized at a point in time in Q3.

Ludvig Lundgren
21:51 - 22:22

Okay. Thank you. Very clear. Yeah. And then just a final one from my side on this matter. So, just on the supply part of it, you take some revenue as well from previous deliveries, if I understand correctly. Yeah. Do you expect this prolongation or new deal to drive any incremental extra sales for the hardware, or is it just running as it has done before? Basically.

Anders Fogelberg
22:24 - 22:43

This contract is primarily the license and consumable business. However, what sometimes happens when you enter this kind of partnership. There are additional opportunities, but there is nothing that we can comment on. But of course, that is in our commercial interest to pursue.

Ewa Linsäter
22:46 - 22:46

Okay.

Ludvig Lundgren
22:46 - 22:46

Thank you.

Ewa Linsäter
22:47 - 22:50

Very clear. We have had in past years. Ludwig.

Ludvig Lundgren
22:50 - 22:54

Yeah. Okay. Great. Thanks. I'll jump back into the queue.

Ewa Linsäter
22:55 - 22:56

Thank you.

Maria Forss
22:57 - 22:57

Thank you.

Operator
22:58 - 23:03

The next question comes from Maria Karlsson Osipova from DNB Carnegie. Please go ahead.

Maria Karlsson Osipova
23:06 - 23:37

Hi. Hello. Thanks for taking my questions. I am going to start with the same topic that you guys started with regarding the CEO transition. Promoting from within the firm is practically as little drama as it can get. So, rather than asking what the drama is since there is no drama, I will flip it. Maria, what is the one thing that you would actually expect to change when he takes over the reins? And maybe for Anders also, could you give us a little bit more color on your immediate priorities once you take the lead on September 1st?

Maria Forss
23:39 - 24:40

Yeah. Now, as you say, Maria, there is no drama in this. I was recruited by the board of directors three years ago with the task of focusing on commercialization, consolidation, and professionalizing the company. As we have presented in the report today, we have come quite far in that transformation. And I recruited Anders Fogelberg as our chief commercial officer, six months into my tenure. And we have worked closely in the past two years together with the rest of the executive team. So together with the board, we have agreed that this is a good time for a shift in leadership. Now that we are entering a new phase, there will be an increased focus on executing our commercialization strategy, continuing our engagement with customers, and ensuring profitable, sustainable growth. So, Anders, in terms of your focus and any comments from you, please?

Anders Fogelberg
24:40 - 25:21

Absolutely. Thank you for the question. And of course, I've been with the company for these two years and with Maria. So in some ways, I will continue what I have done, which is supporting the global customer base, building a commercial engine, and strengthening the market presence. But of course, over the next few months, my executive management team and the board will look at the business, and we might come back with additional perspectives or insights; but for now, when I start the 1st of September, it's all about the commercial engine, operational efficiency, and driving profitable growth.

Maria Forss
25:22 - 25:44

And I will remain as a senior advisor for a quarter to ensure that we have a smooth transition and handover process to Anders. But of course, Anders knows the customers and knows the market, so there is no drama or big deal in this. I really hope that we will have good success moving forward as well, and I am sure that will be the case.

Maria Karlsson Osipova
25:47 - 26:19

All right. Thank you so much for your comments there. And now, a little bit on the numbers. The instrument picture is a bit mixed. We have seen some organic growth now, but instrument sales in total declined. However, you do mention that the benchtop instruments are going well and they are staying strong. Could you maybe quantify a little bit on the split between these benchtop instruments and maybe larger ones that you have, and maybe describe some trends that support your comment that you are gaining confidence in the market recovery?

Maria Forss
26:20 - 27:24

I think overall, if we look at our peers who are operating in the same market, we see the same type of trends in the quarter as everyone else, and I will come to the instrument performance shortly. But first of all, both consumables are increasing by 10%. We also see a slight increase in service, which is also seen by our peers when it comes to instrument sales. Despite the softness in academia, our benchtop instruments are performing very well in several of our business units, which is pleasing to see regarding the instrument decline in the quarter. That is due to the project-based business. That's the reason for the decline. So that has nothing to do with the benchtop industry. Part of our results. That is expected given the lumpiness you see when you start new projects, as there will always be big instrument sales followed by a peak in those quarters where big new projects start. So that is the reason. Anders, do you want to comment anything further?

Anders Fogelberg
27:25 - 27:52

I think our, as you said, Maria, we see what our peers are seeing and there is some improvement in the demand. Everyone sees that the specialized instruments are being sought after. Instruments that are more commodity-based might not have the same demand because of the funding situation, primarily in the US. And we see those dynamics play out in our industry and in our market as well.

Maria Karlsson Osipova
27:56 - 28:18

Yeah. All right. Thank you for the comments there as well. To finish off my short part here with a comment on capital allocation, you mentioned this in Q1, if I am not mistaken. Is there any short follow-up you can give us on those dialogues, for instance, regarding bolt-on acquisitions or something that you referenced in Q1?

Maria Forss
28:20 - 29:09

Thank you for that question. I mean, of course, we are quite happy that we now have a balance sheet in order. We brought in new capital in quarter one, which is a good foundation for continued both organic and inorganic growth, as we have communicated to the market before; smaller bolt-on acquisitions could be opportunities, but we are also increasing our collaborations, such as the one we have with Sartorius, and looking for different collaboration partners. So it's a mix of ensuring that we can continue to invest in R&D, continue to explore strategic and commercial collaborations, as well as looking at potential strategic fit for smaller bolt-on acquisitions.

Maria Karlsson Osipova
29:14 - 29:18

That will be all from me. I will get back in line. Thank you.

Maria Forss
29:19 - 29:20

Thank you. Maria.

Operator
29:22 - 29:26

The next question comes from Philip Einerson from Redeye. Please go ahead.

Philip Einerson
29:29 - 30:03

Hi, everybody. So my question is actually on the services side to start off. I know we have discussed previously the legacy projects within BICO. So my question is whether you could provide some guidance on the expected duration of these legacy projects and what a reasonable expectation would be for how long they will continue to provide a headwind. Um, thank you.

Anders Fogelberg
30:04 - 31:32

Thank you. The legacy projects are something we focus on quite a lot. If you look at the lab automation space and what we are achieving here, these are huge projects, often custom-made hardware and custom-made software solutions in an industry that does not really have standards yet in place. It is quite groundbreaking. We are working with scientists at Big Pharma to set this up in an effective way. It is entrepreneurial work. And as we have communicated many times, some of these bigger projects take longer than anticipated. That is something we face. That is something many of our competitors face as well. Our main priority is to make the customer satisfied with the solution. That is priority number one. We are working very hard and closely with these customers to make that happen. At the same time, as we stated in the quarterly report, we are reassessing the space. What does this mean for us? How can we scale this? How can we scale this in a good way? And how should we be positioned in lab automation to have sustainable, profitable growth? And this is something we are looking at. At the same time, we do our utmost to make our customers happy with what we deliver.

Philip Einerson
31:35 - 31:38

Okay. And then, if I may.

Maria Forss
31:39 - 32:03

I think it is important to distinguish. We talk about lab automation overall, and we do lab automation in most of our companies. So what Anders described now with Biopoint is our lab automation solutions business, which is project-based, but we have a lot of lab automated solutions also with our benchtop instruments. So we do not just say that lab automation is BICO, because that is not the case.

Philip Einerson
32:06 - 32:31

Okay. So, a short follow-up then for me, if you could help us. Are there any of these legacy projects that you think will be completed during 2026? And will this be sort of a fading? Any fading headwinds or anything on that?

Anders Fogelberg
32:32 - 33:22

Yes, we have completed several of these projects. In 2025, we had dozens of them completed, in fact, in quarter four, 2025. If you look at 2026, yes, we have completed some, and we will complete a few more of them. When you look at this business, you have the building phase. When you build it at the factory, you have this system built at the customer site. And then when it gets operational, there is, of course, a service component. And there is an aftermarket component when you work with the scientists on a day-to-day basis. So, in a way, the projects get built, and they get completed. But in a way, they remain continuous for years afterward as partners to these customers.

Philip Einerson
33:25 - 33:39

Okay. That is clear. Thanks. I have one more. So, would you say that the Q2 product mix and share of direct sales is a fair proxy to extrapolate for the second half of the year?

Ewa Linsäter
33:43 - 33:54

We cannot guide you on the forward-looking numbers. But for Q1 and Q2, we saw the desktop instruments growing.

Maria Forss
33:57 - 33:57

So you.

Philip Einerson
33:57 - 33:58

Would.

Maria Forss
33:58 - 33:58

Say that.

Philip Einerson
33:59 - 34:00

Sorry.

Maria Forss
34:00 - 34:01

Please go on.

Philip Einerson
34:02 - 34:17

No. So what I am looking for is more in terms of whether you would say Q2 is sort of an outlier quarter, or is this something we can extrapolate going forward?

Maria Forss
34:17 - 34:35

We are not providing guidance for the future. But as we have reported over the years, our business is quite seasonal, where usually the first half of the year is slower than the second half due to how budgets are allocated in our customers' pockets.

Philip Einerson
34:40 - 34:40

Okay. Thank you.

Operator
34:45 - 34:49

The next question comes from Ludvig Lundgren from Arctic. Please go ahead.

Ludvig Lundgren
34:51 - 35:19

Yes. Hi. So, just a few follow-ups from my side. So first, just on the academic market, which you say is still a bit slow. However, I have heard from some peers that it seems to be turning around now as budgets are not down that much, or not at all, actually on the NIH side. So just some comments on that would be nice.

Anders Fogelberg
35:21 - 36:25

If you look at the NIH funding, which is very important for the academic projects in the US, the way that they fund and the way they pay this funding is a bit different. They pay for longer time periods, they incentivize longer projects, and there are fewer project starts. If you look at their project lists, we had some delays when there was a standstill in Washington, D.C. So there were delays of payments. Then there are fewer starts, which means that those that sell commodities to the academic segment will struggle more than those that sell niche products because commodities are what you normally buy when you start up a lab, whereas the niche products are bought later on in the projects. So if you look at our portfolio, we, like everyone else, are facing challenges when it comes to commodity products.

Ludvig Lundgren
36:29 - 36:53

Okay. Thanks. Very clear. And then just the final one, a bit of a follow-up to the licensing supply agreement question before. So are there any similar types of licensing deals that you have in the pipeline that could be negotiated this way? Or was this a bit of a one-off when it comes to size and so on.

Anders Fogelberg
36:56 - 37:29

Of course, we cannot give guidance on future opportunities, but it is not a very common setup for us to go after these kinds of license agreements. In this case, we have worked with them for several years, and we renegotiated our contracts for several reasons, and we are happy to have this continued trust from this customer. However, it is not a core offering. It is not the core strategy to go after these kinds of contracts.

Ludvig Lundgren
37:33 - 37:37

Okay. Understood. Thanks a lot. That was all my questions.

Operator
37:40 - 37:46

There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.

Maria Forss
37:49 - 37:59

Thank you for all the questions received, and thank you for your continued interest and support in BICO Group and together with Ewa, Anders and Eric. I wish you a great Wednesday.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…